The American College of Radiology Imaging Network (ACRIN) announced in March the
opening of a new clinical trial, titled ''Fluorodeoxyglucose (FDG) as a Predictive Marker of …

Introduction: Structural imaging using CT scanning has long been the standard investigation
for response assessment after chemotherapy, neoadjuvant chemoradiation or definitive …

PET/CT with the glucose analog 18F-FDG has several potential applications for monitoring
tumor response to therapy in patients with non–small cell lung cancer (NSCLC). A …

1746 Objectives: We intended to evaluate whether FDG-PET/CT can predict response to
chemotherapy and survival early in patients with advanced/metastatic non-small cell lung …

Most clinical studies on the use of positron emission tomography with fluorodeoxyglucose
(FDG-PET) in non-small cell lung cancer (NSCLC) have focused on its role in noninvasive …

The aim of this prospective study was to evaluate the value of 18F-FDG PET for the
assessment of chemotherapy response in patients with non–small cell lung cancer …

(NSCLC) is a heterogeneous group of carcinomas with a similar cellular and molecular
origin but different biologic behaviors and prognoses. Accurate staging is essential for …

384 Objectives Novel targeted chemotherapies for cancer work by a number of mechanisms
that can alter the nature of imaging assessment of treatment response. The objective of the …

PET using 18F-FDG is a promising technique to monitor response in oncology.
Unfortunately, a multitude of analytic methods is in use. To date, it is not clear whether …

Editor's note: Barry A. Siegel, MD, known for his pioneering work in nuclear medicine and
clinical PET imaging, was awarded the Benedict Cassen Prize during the 2014 Annual …